Not Just a Biomarker: YKL-40 Links Glial Clock to Amyloidosis
This astrocytic glycoprotein greases glial phagocytosis and reduces plaque burden in mice. The circadian clock protein Bmal1 suppresses it.
ALL NEWS
49 RESULTS
Sort By:
- Most Recent
- Most Commented
Plasma NT1: This Tau Snippet Predicts Cognitive Decline in Alzheimer’s
Among a growing number of blood-based tauopathy markers, this new immunoassay may offer a way to catch preclinical disease just before symptoms show up.
Getting Under Your Skin: Does Vitiligo Elevate Dementia Risk?
In a retrospective study, people with vitiligo had 12 times the risk of developing Alzheimer’s disease than did healthy controls. Why is that?
Does TYROBP-ApoE Signaling Work Independently of TREM2?
This pathway may transmogrify microglia during neurodegeneration, without the help of TREM2.
Better than Crystal Clear? Cryo-EM Achieves Atomic Resolution
Armed with snazzy new hardware, scientists solve protein structures to a resolution of 1.22Å. Cryo-EM now rivals X-ray crystallography.
New Rodent Knock-Ins Carry Humanized Wild-Type APP
Three amino acid substitutions in the Aβ sequence accelerate BACE cleavage of APP and ramp up Aβ production in rats and mice. The mice can serve as better controls for mutant APP knock-ins already in use.
The Microbiome and Disease—What Does Poop Have to Do With It?
Simple lifestyle factors such as alcohol consumption and stool quality alter gut flora. Research on the microbiome and disease should account for those factors, a study reports.
BAN2401 Forges AHEAD into Phase 3, Preclinical AD
The anti-Aβ biologic will be put to the test in two stages of preclinical Alzheimer’s, designated by amyloid load. The long-dormant “est” PET tracer, NAV4694, is on board to make sensitive measurements.
BANish Aβ? BAN2401 Antibody Makes Its Move in Phase 3 Program
At CTAD, a Phase 2 open-label extension of this anti- Aβ protofibril antibody posted data as expected, and new Phase 3 trials for people with early and preclinical Alzheimer’s were described.
TRC-PAD Funnel Finally Touches Down
After years of building an online registry, designing selection algorithms, and getting sites up and running, COVID-19 nearly derailed this trial-ready cohort once again. Now, the first participants have reached the final queue.
Learning Troubles Spied by Smartphone Track with Biomarkers
Remote assessments on a smartphone closely matched tests taken in the clinic. They also may detect slip-ups in learning—an earlier cognitive deficit that arises in preclinical AD.
In Phase 2 Trial, Neflamapimod Aids Cognition in Lewy Body Dementia
After missing primary endpoints in Alzheimer’s trials, this p38 MAPKa inhibitor gained some traction in a test in people with DLB.
Clinical Trials on Alzheimer's Disease (CTAD) 2020 (Virtual Meeting)
BANish Aβ? BAN2401 Antibody Makes Its Move in Phase 3 Program BAN2401 Forges AHEAD into Phase 3, Preclinical AD TRC-PAD Funnel Finally Touches Down Learning Troubles Spied by Smartphone Track with Biomarkers In Phase 2 Trial, Neflamapimod Aids Cognition ...
Microglia in Tauopathy: Not Just Homeostatic Versus DAM
In mouse models of tauopathy, microglia populations are far from binary. Different activation stages emerge at different phases of disease, some marked by viral defense pathways.
You Are What You Breathe: Polluted Air Tied to Plaques, Brain Atrophy
Two cohorts—IDEAS and WHIMS—show Aβ accumulation and brain shrinkage in cognitively normal and impaired elderly who were exposed to levels of air pollution even within current EPA limits.
Current Filters
- Date Range : Oct 2020 to Jan 2021 x